Calidi Biotherapeutics's total assets for Q3 2024 were $6.66M, an increase of 3.51% from the previous quarter. CLDI total liabilities were $16.45M for the fiscal quarter, a -9.50% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.